Maryland State Retirement & Pension System Purchases 8,393 Shares of Gilead Sciences, Inc. $GILD

Maryland State Retirement & Pension System boosted its position in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 12.5% in the third quarter, Holdings Channel.com reports. The firm owned 75,589 shares of the biopharmaceutical company’s stock after purchasing an additional 8,393 shares during the period. Maryland State Retirement & Pension System’s holdings in Gilead Sciences were worth $11,267,000 as of its most recent SEC filing.

A number of other institutional investors have also recently bought and sold shares of the company. UNIVEST FINANCIAL Corp acquired a new stake in shares of Gilead Sciences during the 3rd quarter valued at about $275,000. Joel Isaacson & Co. LLC grew its stake in shares of Gilead Sciences by 12.3% in the 3rd quarter. Joel Isaacson & Co. LLC now owns 1,938 shares of the biopharmaceutical company’s stock valued at $289,000 after buying an additional 213 shares in the last quarter. Valued Wealth Advisors LLC grew its stake in shares of Gilead Sciences by 14.1% in the 3rd quarter. Valued Wealth Advisors LLC now owns 744 shares of the biopharmaceutical company’s stock valued at $111,000 after buying an additional 92 shares in the last quarter. First Command Advisory Services Inc. increased its holdings in Gilead Sciences by 124.9% in the third quarter. First Command Advisory Services Inc. now owns 704 shares of the biopharmaceutical company’s stock worth $105,000 after buying an additional 391 shares during the last quarter. Finally, Machina Capital S.A.S. acquired a new position in Gilead Sciences in the third quarter worth approximately $4,935,000. Institutional investors and hedge funds own 83.67% of the company’s stock.

Insider Buying and Selling

In other news, CEO Daniel O’Day sold 9,810 shares of Gilead Sciences stock in a transaction that occurred on Thursday, November 5th. The shares were sold at an average price of $175.17, for a total value of $1,718,417.70. Following the transaction, the chief executive officer owned 551,683 shares of the company’s stock, valued at $96,638,311.11. This trade represents a 1.75% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Andrew D. Dickinson sold 3,000 shares of the business’s stock in a transaction on Thursday, October 15th. The stock was sold at an average price of $156.22, for a total transaction of $468,660.00. Following the completion of the sale, the chief financial officer owned 161,096 shares of the company’s stock, valued at $25,166,417.12. The trade was a 1.83% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 242,709 shares of company stock worth $39,503,427 over the last ninety days. Company insiders own 0.30% of the company’s stock.

More Gilead Sciences News

These are some of the GILD news items that stood out recently:

• Positive Sentiment: Gilead reported PURPOSE 5 results showing twice-yearly injectable lenacapavir outperformed daily oral HIV prevention on persistence, with no HIV infections in the injectable group. The findings could strengthen the long-term opportunity for its HIV prevention franchise. Gilead Sciences Posts PURPOSE 5 Win As HIV Shot Beats Daily Pills
• Positive Sentiment: Recent coverage also points to clinical progress in HIV and liver disease and raised full-year guidance, supporting confidence in Gilead’s outlook. Its latest reported quarter beat analyst estimates for earnings and revenue, with revenue up year over year. Gilead Sciences After Trial Wins And Raised Guidance Looks Fully Valued
• Neutral Sentiment: Gilead partner Xilio expects to provide Gilead with an option data package for efarindodekin alfa in the first half of 2027. This is a potential pipeline catalyst, but remains several months away and is dependent on future data. Xilio Therapeutics Pipeline Update

Gilead Sciences Price Performance

Shares of NASDAQ:GILD opened at $169.73 on Thursday. The stock has a market capitalization of $210.52 billion, a P/E ratio of -53.71 and a beta of 0.35. The business has a 50-day moving average of $154.40 and a two-hundred day moving average of $141.51. Gilead Sciences, Inc. has a fifty-two week low of $116.88 and a fifty-two week high of $176.58. The company has a debt-to-equity ratio of 1.84, a current ratio of 1.38 and a quick ratio of 1.22.

Gilead Sciences (NASDAQ:GILD) last issued its quarterly earnings data on Thursday, October 29th. The biopharmaceutical company reported $2.55 EPS for the quarter, beating analysts’ consensus estimates of $2.19 by $0.36. Gilead Sciences had a negative return on equity of 1.85% and a negative net margin of 12.47%. The business had revenue of $8.30 billion for the quarter, compared to analyst estimates of $7.81 billion. During the same quarter in the prior year, the firm posted $2.47 EPS. The firm’s revenue for the quarter was up 6.8% on a year-over-year basis. On average, equities research analysts predict that Gilead Sciences, Inc. will post -0.98 EPS for the current fiscal year.

Gilead Sciences Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Wednesday, December 30th. Shareholders of record on Tuesday, December 15th will be given a dividend of $0.82 per share. The ex-dividend date of this dividend is Tuesday, December 15th. This represents a $3.28 dividend on an annualized basis and a yield of 1.9%. Gilead Sciences’s dividend payout ratio is presently -103.80%.

Wall Street Analysts Forecast Growth

GILD has been the topic of several recent research reports. TD Cowen raised their price objective on shares of Gilead Sciences from $160.00 to $175.00 and gave the company a “buy” rating in a research report on Friday, October 30th. Royal Bank Of Canada lifted their target price on shares of Gilead Sciences from $126.00 to $131.00 and gave the company a “sector perform” rating in a research note on Friday, October 30th. Leerink Partners downgraded shares of Gilead Sciences from an “outperform” rating to a “market perform” rating and decreased their target price for the stock from $146.00 to $127.00 in a research report on Tuesday, July 21st. Wells Fargo & Company increased their price target on shares of Gilead Sciences from $165.00 to $190.00 and gave the stock an “overweight” rating in a research note on Friday, October 30th. Finally, Needham & Company LLC set a $175.00 price target on shares of Gilead Sciences in a report on Friday, October 30th. Twenty-three research analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $170.15.

Gilead Sciences Company Profile

Gilead Sciences, Inc. is a biopharmaceutical company that discovers, develops and commercializes medicines for serious diseases. Founded in 1987 and headquartered in Foster City, California, the company focuses on antiviral therapies, including treatments and preventive medicines for HIV and medicines for viral hepatitis. Its products include Biktarvy for HIV and Epclusa for hepatitis C. Gilead also develops medicines in areas such as oncology and inflammatory diseases. Its portfolio includes Veklury (remdesivir), an antiviral medicine used to treat COVID-19.